• Journal of Nutrition and Health
• /
• v.35 no.1
• /
• pp.45-52
• /
• 2002

This study was to investigate 1) the correlation of serum Ca, with depression and anxiety ; and 2) the effect of Ca intake on those symptoms. The subjects were three females and two males who were 53-66 years old with the severe subjective symptoms of depression and anxiety. They have taken more than twice Ca of RDA(recommended dietary allowances for Koreans) daily for 6 months(dietary treatment). The prestudy Ca intake of the subjects was low: 60% of RDA for Koreans. Their serum Ca concentration was also low: 6.67 $\pm$ 0.15mg/d1 before the dietary treatment. They expressed severs depression and anxiety, with high self scores in a psychological test. Their serum Ca concentration increased to 8.32 $\pm$ 0.17mg/dl after six months of dietary treatment, while the symptoms of depression and anxiety decreased significantly after two months and nearly disappeared after six months. This result seemed to be an effect of the dietary high Ca intake. Serum Ca and the psychological states of depression and anxiety correlated negatively, and the coefficients of determination were high in the results of linear regression analysis of depression and anxiety by serum Ca. Therefore the serum Ca concentration could be a good marker to predict depression or anxiety relatively well. The continuous high Ca intake could decrease the probability of developing depression or anxiety and mitigate their symptoms because serum Ca concentration increased, while the state of depression and anxiety decreased with the increased Ca intake.

• The Korean Journal of Nuclear Medicine
• /
• v.19 no.1
• /
• pp.119-126
• /
• 1985

To evaluate the performance characteristics of CA 19-9 radioimmunoassay and the clinical significance of serum CA 19-9 assay in patients with malignancy, serum CA 19-9 levels were measured by radioimmunoassay using monoclonal antibody in 135 normal controls, 81 patients with various untreated malignancy, 9 patients of postoperative colon cancer without recurrence and 20 patients with benign gastrointestinal diseases, who visited Seoul National University Hospital from June, 1984 to March, 1985. The results were as follows; 1) The CA 19-9 radioimmunoassay was simple to perform and can be completed in one work day. And the between-assay reproducibility and the assay recovery were both excellent. 2) The mean serum CA 19-9 level in 135 normal controls was $8.4{\pm}4.2U/mL$. Normal upper limit of serum CA 19-9 was defined as 21.0 U/mL. 4 out of 135(3.0%) normal controls showed elevated CA 19-9 levels above the normal upper limit. 3) One out of 20(5.0%) patients with benign gastrointestinal diseases showed elevated serum CA 19-9 level above the normal upper limit. 4) In 81 patients with various' untreated malignancy, 41 patients(50.6%) showed elevated serum CA 19-9 levels. 66.7% of 18 patients with colorectal cancer, 100% of 2 patients with pancreatic cancer, 100% of 3 patients with common bile duct cancer, 47.1% of 17 patients with stomach cancer, 28.6% of 28 patients with hepatoma and 60.0% of 5 other gastrointestinal tract cancers showed elevated serum CA 19-9 levels. 5) The sensitivities of serum CA 19-9 related to resectability in colorectal and stomach cancer were 33.3% in resectable colorectal cancer, 83.3% in unresectable colorectal cancer, 41.7% in resectable stomach cancer, 60.0% in unresectable stomach cancer respectively. 6) The sensitivity of serum CA 19-9 in 9 patients of postoperative colorectal cancer without recurrence were 33.3% and significantly decreased compared with that of untreated colorectal cancer, 66.7% (p<0.05). 7) In patients with colorectal cancer, simultaneous measurement of serum CA 19-9 and serum CEA levels increased sensitivities. From above results, we concluded that serum CA 19-9 radioimmunoassay is simple to perform and reproducible, and is a useful indicator reflecting tumor extent and responses to the treatment in patients with malignancy.

• Asian-Australasian Journal of Animal Sciences
• /
• v.28 no.1
• /
• pp.58-68
• /
• 2015

Requirements to control the large decrease in serum calcium (Ca) due to parturition and to increase the feed intake soon after parturition have been well accepted in dairy cows. This study was aimed to investigate the feed intake affected by serum Ca concentration with difructose anhydride (DFA) III supplement in dairy cows soon after parturition. Fourteen transition Holstein cows were divided into DFA and control (CONT) groups within 1 to 5 parity variations in each group. Measurement schedule for an individual cow was from 14 d before parturition to 7 d following parturition. The cows in DFA group were supplied 0.2 kg/head/d of DFA III feed containing 40 g of pure DFA III while the cows in CONT group received no DFA III. Other feeding procedures were the same for all cows in both groups. At parturition (d 0), serum Ca concentration sharply declined in both groups (p<0.05). Time interval for recovery from decreased serum Ca to its normal range (>9.0 mg/dL) tended to be faster in DFA group (12 h) than in the CONT group (48 h), but the differences were not significant. Active ruminal contraction was observed in DFA group at following parturition of d 1 (p<0.05), d 3 (p<0.05), and d 5 (p<0.01). Dry matter (DM) intake did not differ between the groups. However, positive correlations were observed between serum Ca concentration and ruminal contraction (p<0.001), and between ruminal contraction and DM intake (p<0.001) during following parturition. According to multiple regression analysis ($R^2$ = 0.824, p<0.001), the DM intake was positively affected by serum Ca concentration and ruminal contraction. These results suggest that feed intake soon after parturition in dairy cows can be increased by improvement of serum Ca concentration and active ruminal contraction, but DFA III supplementation in this study did not improve the lower serum Ca concentration due to parturition.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.8
• /
• pp.4199-4202
• /
• 2012

Objective: The aim of our study is to compare an ovarian malignancy prediction model based on age and four sonographic findings (OMPS1) with a new model called OMPS2 which differs just by adding serum CA125 measurement to (OMPS1). Methods: In a cross sectional comparative study OMPS1 was validated in 830 operated ovarian masses within a 3 years period (2006-2009). Logistic regression analysis was used to construct OMPS2 based on OMPS1 adding serum CA125 findings. The area under the curve for two models was compared in 411 patients. Results: OMPS2 was calculated as follows: OMPS1 + 1.444 (if serum CA125= 36-200) or 3.842 (if serum CA125 is more than 200). AUC of OMPS2 was increased to 84.3% (CI 95% 78.1- 89.8) in comparison to OMPS1 with AUC of 78.1% (CI 95% 71.8-84.5). Conclusion: Our second model is more accurate in prediction of ovarian malignancy, compared with our first model.

• Asian Pacific Journal of Cancer Prevention
• /
• v.17 no.1
• /
• pp.323-333
• /
• 2016

Background: Ovarian cancer remains a major worldwide health care issue due to the lack of satisfactory diagnostic methods for early detection of the disease. Prior studies on the role of serum cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in detecting ovarian cancer presented conflicting results. New tools to improve the accuracy of identifying malignancy are urgently needed. We here aimed to evaluate the diagnostic utility of tissue CA125 and HE4 gene expression in comparison to serum CA125 and HE4 in discriminating benign from malignant pelvic masses. Materials and Methods: One-hundred Egyptian women were enrolled in this study, including 60 epithelial ovarian cancer (EOC) patients and 20 benign ovarian tumor patients, as well as 20 apparently healthy women. Preoperative serum levels of CA125 and HE4 were measured by immunoassays. Tissue expression levels of genes encoding CA125 and HE4 were determined by quantitative real time polymerase chain reaction (qRT-PCR). The diagnostic performance of CA125 and HE4, measured either as mRNA or protein levels, was evaluated by receiver operating characteristic (ROC) curves. Results: The serum CA125+HE4 combination and serum HE4, with area under the curve (AUC) values of 0.935 and 0.932, respectively, performed significantly better than serum CA125 (AUC=0.592; P<0.001). Tissue CA125 and HE4 (AUC=1) performed significantly better than serum CA125 (P<0.001), serum HE4 (P=0.016) and the serum CA125+HE4 combination (P=0.018). Conclusions: Measurement of tissue CA125 and HE4 gene expression not only improves discriminatory performance, but also broadens the range of differential diagnostic possibilities in distinguishing EOC from benign ovarian tumors.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.8
• /
• pp.4545-4548
• /
• 2013

The objective of this study is to assess tissue expression of CA-125 and HE4 protein in primary benign and malignant epithelial tumours of the ovary and correlate with serum CA-125 levels. A total of 100 formalin-fixed, paraffin embedded sections of ovarian tumours which included serous adenoma (11), mucinous adenoma (42), serous carcinoma (20), mucinous carcinoma (12) and endometrioid carcinoma (15), histologically diagnosed between $1^{st}$ January 2004 to $31^{st}$ December 2012 at the University Malaya Medical Centre, were stained for HE4 (rabbit polyclonal antibody, Abcam, UK) and CA-125 (mouse monoclonal antibody clone: OC125, Cell Marque Corporation, Rocklin, California, USA). Pre-operative serum CA-125 levels were obtained from the laboratory information system. Immunoscore (I score) for HE4 and CA-125 was given based on the intensity of staining and percentage of positive tumour cells and considered significant when it was >50 (intensity of staining multiplied by percentage of positive tumour cells). Serum CA-125 levels were compared with the I score of HE4 and CA-125 in tissues. We noted that the CA-125 levels in serum and tissues were significantly raised in malignant compared to benign ovarian tumours (p value<0.05). Tissue expression of HE4 protein was also significantly raised in malignant tumours compared to benign tumours (p value<0.05). We conclude that HE4 can be a useful tissue immunomarker in addition to CA-125.

• Tuberculosis and Respiratory Diseases
• /
• v.72 no.6
• /
• pp.507-510
• /
• 2012

Carbohydrate antigen 19-9 (CA19-9) is a specific tumor marker of the biliary, pancreatic and gastrointestinal tracts. CA19-9 is occasionally elevated in serum in patiens with benign pulmonary diseases such as bronchiectasis, idiopathic interstitial pneumonia or collagen disease-associated pulmonary fibrosis. Intralobar pulmonary sequestration is an uncommon congenital lung anomaly. It is dissociated from the normal tracheobronchial tree and is supplied by an anomalous systemic artery. There have been some reports of elevation of CA19-9 in this lesion. We report a case of intralobar pulmonary sequestration with elevated serum CA19-9 in a 29-year-old man who was diagnosed with bronchiectasia of left lower lung field on general check up. He had no evidence of any malignant disease in pancreatobiliary or gastrointestinal tracts. Elevated serum CA19-9 level might be encountered with benign pulmonary disease such as pulmonary sequestration.

• Tuberculosis and Respiratory Diseases
• /
• v.64 no.5
• /
• pp.383-386
• /
• 2008

An elevated serum CA19-9 level is an indication of pancreatic and biliary tract cancer. However, it has recently become known that nonmalignant gastrointestinal diseases and a variety of nonmalignant respiratory diseases, such as idiopathic interstial pneumonia, collagen vascular disease associated lung diseases, diffuse panbronchiolitis and bronchiectasis, can also show an elevated serum CA19-9 level. We recently encountered a case of bronchiectasis with persistently elevated serum CA19-9, but without any evidence of malignant disease in endoscopic retrograde pancreatocholangiography, abdominal computed tomography, and positron emission tomography. After serial follow-up of 3 years and 10 months, there was still no evidence of cancer. It is believed that the elevated serum CA19-9 level was due to bronchiectasis. An elevated serum CA19-9 level should be interpreted carefully with the patients' clinical condition.

• Journal of Nutrition and Health
• /
• v.24 no.2
• /
• pp.114-123
• /
• 1991

This study was designed to investigate the effects of aerobic dancing and/or Ca supplemen-tation for six months on Ca metabolism in postmenopausal women. The subjects were healthy 29 women aged from 60 to 70 years old. They were divided into four groups ; placebo and Ca supplementation group with and without exercise. The amount of Ca supplemented was 500mg a day. The frequency of doing exercise was three times a week and it took 40 minutes to complete once all the course of aerobic dancing programmed for old women. The results were summarized as follows : 1) Bone density of the second lumbar spine and ward's triangle measured after experiment decreased significantly in control group as compared with pre-experimental level(P<0.05). On the contrary it showed a tendency to increase or maintained the pre-experimental level after experiment in other groups. 2) Urinary Ca/creatinine and P/creatinine ratios did not show any significant differences among groups before and after experiment. But urinary Ca/creatinine ration decreased signifi-cantly in Ca group after experiment(P<0.05) 3) Serum Ca and P levels did not show any significant differences among groups before and after experiment. But serum Ca level in creased significantly in Ca group after experiment(P<0.05) 3) Serum Ca and P levels did not show any significant differences among groups before and after experiment. But serum Ca level increased significantly in Ca group after experiment (P<0.05). 4) Serum PTH level also did not show any significant differences among groups before and after experiment. But serum calcitonin level decreased significantly in Ca group after experiment(P<0.05). The above results showed that it will be difficult to prevent degenerative bone loss without regular exercise and/or Ca supplementation in postmenopausal women having Korean usual diets.

• Clinical and Experimental Reproductive Medicine
• /
• v.17 no.2
• /
• pp.101-106
• /
• 1990

Serum CA 125 was measured with immunoradiometric assay in fourty-one patients of endometriosis Serum CA 125 levels (Mean ${\pm}$ SEM, U/ml)in patients with endometriosis were 13.8${\pm}$3.3 in stage I , 17.3${\pm}$3.0 in stage II, 23.4${\pm}$4.9 in stage III, and 64.5${\pm}$13.2 in stage IV, which showed increment according to the stage of endometriosis. Serum levels in stage IV only were significantly elvated than those in control (15.3${\pm}$2.2), and those in advanced stage(III and IV ; 47.1${\pm}$9.5)were significantly higher than those in earlier stages (15.9${\pm}$2.2)and control. The assay revealed a sensitivity of 31.7% and the frequency of elevated levels (> 30.3 U/ml)in stage I, II, III and IV was 9. 1%, 18.8%,33.3%, and 87.5% respectively. Sensitivity in advanced stage was higher than that in earlier stage (64.3% vs. 14.8%). There data suggest that serum CA 125 assay might be a useful diagnostic tool in the advanced stage of endometriosis.